Antibody-drug conjugates (ADCs): all 1,111 studies that test it
Page 1 of 12. Open to participants first (502), then studies with results posted, then the rest; newest registration first within each.
- Sac-TMT in Salivary Gland CancersNot yet recruitingNCT07928193Phase 2
- Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate CancerNot yet recruitingNCT07925268Phase 2
- Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLNot yet recruitingNCT07921550Not applicable
- Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan TrialNot yet recruitingNCT07910435Phase 2
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerRecruitingNCT07908979Phase 2
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective StudyRecruitingNCT07908888Phase 4
- MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Not yet recruitingNCT07908524Phase 1/2
- Sacituzumab Tirumotecan Plus Toripalimab for Advanced Penile Cancer After Platinum ChemotherapyNot yet recruitingNCT07907861Phase 2
- Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)Not yet recruitingNCT07905313Phase 2
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingNCT07890714Phase 1/2
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingNCT07883135Phase 2
- Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerNot yet recruitingNCT07879469Phase 2
- Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaNot yet recruitingNCT07863765Phase 2
- Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic LeukemiaNot yet recruitingNCT07862946Phase 2
- A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI FailureNot yet recruitingNCT07854509Phase 2
- DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder CancerNot yet recruitingNCT07853053Phase 1
- A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract CancerRecruitingNCT07850791Phase 2
- Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Not yet recruitingNCT07831122Phase 1
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)RecruitingNCT07829783Phase 3
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingNCT07825753Phase 2
- Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07823270Phase 2
- A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial CancerNot yet recruitingNCT07822373Phase 2
- Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07819578Phase 2
- Sacituzumab Tirumotecan as Second-Line Treatment for Penile CancerNot yet recruitingNCT07815197Phase 2
- Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal CancerRecruitingNCT07811752Phase 2
- Sac-TMT in Vaginal and Vulvar CancersNot yet recruitingNCT07804966Phase 2
- Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain MetsNot yet recruitingNCT07789444Phase 2
- A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast CancerNot yet recruitingNCT07782086Not applicable
- Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCNot yet recruitingNCT07750704Phase 2
- A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic CarcinomasNot yet recruitingNCT07750353Phase 2
- Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07748689Phase 2
- Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT07741630Phase 2
- A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland CarcinomaNot yet recruitingNCT07740993Phase 2
- SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological MalignanciesNot yet recruitingNCT07738757Phase 2
- A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.Not yet recruitingNCT07729033Phase 2
- TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Not yet recruitingNCT07720843Phase 1
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingNCT07720284Phase 3
- Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination TherapyNot yet recruitingNCT07720258Phase 2
- Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell CancerRecruitingNCT07718854Phase 2
- AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCLNot yet recruitingNCT07717177Phase 2
- Genitourinary Tumors With Sacituzumab TirumotecanNot yet recruitingNCT07716917Phase 2
- A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOPNot yet recruitingNCT07702851Phase 2
- Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung CancerNot yet recruitingNCT07702305Phase 1
- A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerRecruitingNCT07701941Phase 1/2
- Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07701681Phase 2
- Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract CancerNot yet recruitingNCT07701122Phase 2
- SKB264 in Combination With SKB118 for Non-Small Cell Lung CancerRecruitingNCT07697586Phase 2
- A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal CancerNot yet recruitingNCT07691489Phase 2
- Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07689292Phase 2
- Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07686588Phase 2
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingNCT07683754Phase 3
- Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell LymphomaNot yet recruitingNCT07677813Phase 2
- IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian CancerNot yet recruitingNCT07674615Phase 1
- Tisotumab Vedotin in Squamous Cell Carcinoma of the VulvaNot yet recruitingNCT07672782Phase 2
- SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II StudyRecruitingNCT07670013Phase 2
- Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBCNot yet recruitingNCT07663747Phase 2
- Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)Not yet recruitingNCT07662863Phase 2
- The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over ExpressionNot yet recruitingNCT07662473Phase 2
- Optimal Application Timing of ADC Drugs for Advanced Breast CancerRecruitingNCT07657130Phase 2
- The CARDIOPROTECT TrialNot yet recruitingNCT07654426Phase 2
- EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBCRecruitingNCT07647289Phase 2
- Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder CancerRecruitingNCT07646145Phase 2
- Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial CarcinomaNot yet recruitingNCT07643519Phase 2
- Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella TrialNot yet recruitingNCT07643103Phase 2
- Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior ChemotherapyNot yet recruitingNCT07639086Phase 2
- A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)RecruitingNCT07630974Phase 1/2
- Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA MutationsNot yet recruitingNCT07628504Phase 3
- Sac-TMT Combined With Bevacizumab in TNBC With Brain MetastasesRecruitingNCT07623577Phase 2
- Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaRecruitingNCT07619521Phase 1/2
- Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast CancerNot yet recruitingNCT07619365Phase 2
- Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07614360Phase 2
- A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic ImpairmentNot yet recruitingNCT07609706Phase 1
- HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBCNot yet recruitingNCT07608224Phase 2/3
- HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUCNot yet recruitingNCT07591805Phase 2
- SKB118 Injection in Advanced Solid TumorsRecruitingNCT07586943Phase 1/2
- Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial CarcinomaNot yet recruitingNCT07584733Phase 2
- Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)RecruitingNCT07573436Phase 1/2
- Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaNot yet recruitingNCT07572123Phase 2/3
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingNCT07566156Phase 3
- Sacituzumab Tirumotecan for Pancreatic CancerNot yet recruitingNCT07561463Phase 2
- A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based ChemotherapyRecruitingNCT07548060Phase 2
- Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver MetastasisNot yet recruitingNCT07545213Phase 2
- Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular ImagingNot yet recruitingNCT07527806Phase 2
- Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)Not yet recruitingNCT07521670Phase 2
- Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/RectumNot yet recruitingNCT07511023Phase 2
- Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal CanceNot yet recruitingNCT07509424Phase 2
- A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric CancerNot yet recruitingNCT07507526Phase 2
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingNCT07504588Phase 2
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingNCT07502872Phase 2
- Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Not yet recruitingNCT07501169Phase 2
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial CarcinomaRecruitingNCT07498907Phase 3
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT07492914Phase 2
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)RecruitingNCT07476729Phase 3
- A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderRecruitingNCT07475806Phase 2
- Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical TrialRecruitingNCT07474324Phase 2
- HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term RemissionRecruitingNCT07459673Phase 2
- Sac-TMT for Active TNBC Brain MetastasesNot yet recruitingNCT07458113Phase 2
- Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain MetastasesNot yet recruitingNCT07454668Phase 1
- Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingNCT07446452Phase 2
- Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary CarcinomaRecruitingNCT07438626Phase 2